Viking Therapeutics' obesity drug shows durable weight-loss benefit, shares jump
VK2735 obesity drug maintained up to 97% of prior weight loss with less frequent dosing, lifting shares 40% as it advances injectable and oral options for a market projected to hit $100B by 2030
Reuters1 min read
Share

Add Emirates 24|7 to your Google News
Text Size:
